President Donald Trump on Wednesday announced broad global tariffs, including a 20% tariff on Europe, in a move that pharma ...
The FTC’s legal fight against three major pharmacy benefit managers is on hold after two agency commissioners have been ...
BIO CEO John Crowley sat down for an exclusive interview that covered tariffs, collaborating with RFK Jr., and investing in ...
Tang Capital’s shell company Concentra Biosciences secured its first major deal since late 2023. Allakos has agreed ...
Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in ...
Eli Lilly’s direct-to-consumer service added knownwell to its line-up of providers who can prescribe its medications, as it ...
Arie Belldegrun's life sciences venture firm secured a pair of new managing directors after parting ways with two leaders ...
New CDMO Artis BioSolutions has come out of stealth and is snapping up cell and gene therapy manufacturer Landmark Bio for an ...
Edgewise Therapeutics' EDG-7500 shows positive Phase 2 results in heart muscle disease trial, reducing LVOT-G by up to 71%.
Eli Lilly has sued two large compounding pharmacies, alleging they deceive patients and put them at risk with compounded ...
The European Medicines Agency is looking to simplify the way it approves biosimilars by removing the need for “extensive” clinical data, which would likely cut the cost of entry into the market.
Atsena Therapeutics raises $150M Series C, led by Bain Capital Life Sciences, to advance ATSN-201 gene therapy for X-linked retinoschisis through FDA application.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback